Fidelity Disruptive Medicine ETF (FMED)

Overview

The Fidelity Disruptive Medicine ETF (FMED) aims to invest in companies that are engaged in activities in the disruptive medicine segment. This includes companies involved in gene therapy, precision medicine, and robotic surgery. The ETF seeks long-term growth by focusing on the healthcare sector, specifically those innovating medicine through technology.

Reputation and Reliability

Fidelity is a well-established and reputable asset manager with a long history in the financial industry, known for offering a wide range of investment products and services.

Management Expertise

Fidelity has a team of experienced investment professionals managing its ETFs, leveraging their expertise in healthcare and technology sectors.

Goal

FMED aims for long-term capital appreciation by investing in companies involved in disruptive medicine.

Investment Approach and Strategy

Strategy: FMED does not track a specific index but rather uses a discretionary investment approach, selecting companies based on their potential in disruptive medicine.

Composition The ETF primarily holds stocks of companies involved in areas like gene therapy, robotic surgery, and precision medicine. The composition is actively managed.

Market Share: Insufficient data available to accurately determine FMED's precise market share.

Total Net Assets (AUM): 112530474

Key Competitors

• ARK Genomic Revolution ETF (ARKG)
• iShares Genomics Immunology and Healthcare ETF (IDNA)
• Loncar Cancer Immunotherapy ETF (CNCR)

Competitive Landscape

The disruptive medicine ETF market is competitive, with several ETFs vying for investor attention. FMED competes with other thematic ETFs focusing on genomics and biotechnology. FMED's advantage lies in Fidelity's research capabilities, while disadvantages may stem from its relatively smaller AUM compared to ARKG. FMED provides similar investment strategies, potentially lower expense ratios, and a well known established brokerage brand name. The market share percentage comparison shows data for this is not readily available.

Historical Performance: Historical performance data should be obtained from official fund fact sheets or financial data providers. Data will be provided in a future version.

Benchmark Comparison: Benchmark comparison should be done against a broad healthcare or biotechnology index, such as the S&P Biotechnology Select Industry Index. Data will be provided in a future version.

Expense Ratio: 0.5

Average Trading Volume

The average trading volume of FMED indicates moderate liquidity, facilitating relatively easy buying and selling of shares.

Bid-Ask Spread

The bid-ask spread is generally tight, reflecting the ETF's liquidity and indicating reasonable trading costs.

Market Environment Factors

FMED is affected by factors such as advancements in medical technology, regulatory changes, and investor sentiment towards the healthcare sector and biotech industry.

Growth Trajectory

The growth trajectory of FMED depends on the continued innovation in disruptive medicine and investor appetite for thematic investments in healthcare. Changes to strategy would likely involve adjusting sector allocations within disruptive medicine.

Competitive Edge

FMED benefits from Fidelity's extensive research resources and brand recognition, enabling in-depth analysis of disruptive medicine companies. Fidelity's established distribution network enhances the ETF's accessibility to a broad investor base. The active management approach allows FMED to adapt to the rapidly evolving landscape of the disruptive medicine sector. FMED benefits from a solid brand reputation and a well known financial institution with great financial backing.

Volatility

FMED's volatility is expected to be high due to the nature of disruptive medicine companies, which often involve significant research and development risks. Data will be provided in a future version.

Market Risk

Specific risks include regulatory hurdles, clinical trial failures, and competition from established pharmaceutical companies, impacting the performance of FMEDu2019s holdings.

Ideal Investor Profile

The ideal investor is one who is seeking long-term growth potential and is comfortable with the volatility associated with investing in disruptive medicine companies.

Market Risk

FMED is best suited for long-term investors with a high-risk tolerance and a strong belief in the potential of disruptive medicine.

The Fidelity Disruptive Medicine ETF (FMED) offers investors exposure to companies at the forefront of medical innovation, including gene therapy and robotic surgery. Managed by Fidelity, it benefits from their research resources, although it faces competition from other thematic ETFs. With a moderate expense ratio, FMED is suitable for risk-tolerant, long-term investors believing in the transformative potential of disruptive medicine. Investors should consider both the risks and rewards of investing in this innovative sector. FMED presents an intriguing opportunity to participate in the future of medicine.

• ARKG
• IDNA
• CNCR
• XBI
• IBB
• PJP

Data Sources:

• Fidelity Investments, ETF.com, Bloomberg
• Other sources will be added here as utilized

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investors should conduct their own research and consult with a financial advisor before making any investment decisions. Market share and AUM can fluctuate.